All In Biotech

NDA 021135 · Am Regent

Venofer

Iron Sucrose · Intravenous · Parenteral Iron Replacement

Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Nov 6, 2000

Approved uses

5

Original approval plus efficacy supplements

Registered trials

125

33 Phase 3, 7 recruiting

FAERS reports

9,664

7,633 serious, 935 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 1, 2026.

Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). Venofer is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). ( 1 )

Mechanism: Venofer is an aqueous complex of poly-nuclear iron (III)-hydroxide in sucrose. Following intravenous administration, Venofer is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron in the precursor cells is incorporated into hemoglobin as the cells mature into red blood cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • VENOFER · IRON SUCROSE EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Discontinued
  • VENOFER · IRON SUCROSE EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Discontinued
  • VENOFER · IRON SUCROSE EQ 100MG IRON/5ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB
  • VENOFER · IRON SUCROSE EQ 200MG IRON/10ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB
  • VENOFER · IRON SUCROSE EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) · INJECTABLE, INTRAVENOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Iron Sucrose" as an intervention, any sponsor and status, largest first.

All 125 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity1,169
  • nausea1,035
  • dyspnoea1,014
  • off label use654
  • pruritus651
  • vomiting647
  • diarrhoea554
  • rash550
  • hypotension530
  • dizziness520
  • urticaria495
  • headache473

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200448
200568
200686
2007141
2008157
2009270
2010240
2011190
2012269
2013299
2014277
2015384
2016444
2017420
2018485
2019843
2020589
2021690
2022904
2023814
2024716
2025704
2026626

Recalls

3 FDA enforcement reports for this application.

  • Nov 11, 2024 · Class II · Ongoing

    Presence of Particulate Matter: Potential for glass delamination from the vials.

  • Nov 11, 2024 · Class II · Ongoing

    Presence of Particulate Matter: Potential for glass delamination from the vials.

  • Nov 11, 2024 · Class II · Ongoing

    Presence of Particulate Matter: Potential for glass delamination from the vials.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Venofer (Iron Sucrose Complex)

2024 spending

$22K

Beneficiaries

44

80 claims

Per beneficiary

$504

$11.88 per unit

View as table
YearSpending
2020$0
2021$0
2022$5,736
2023$0
2024$22,188

Part B: Venofer (Iron Sucrose Complex) · HCPCS J1756

2024 spending

$3.0M

Beneficiaries

15,093

64,302 claims

Per beneficiary

$200

2024 ASP limit $0.23 per unit

View as table
YearSpending
2020$2,411,573
2021$2,713,532
2022$3,100,943
2023$3,631,028
2024$3,011,707

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 207 on PubMed

Sponsor: Am Regent

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.